1. "Gastrointestinal Oncology Service"
Formats
  1. Journal Article (2302)
  2. Meeting Abstract (1841)
  3. Review (139)
  4. Book Section (123)
  5. Editorial (93)
  6. Guidelines (36)
  7. Correspondence (33)
  8. Conference Paper (23)
  9. Miscellaneous (21)
  10. Research Letter (17)
  11. Book Whole (12)
Groups
  1. Gastrointestinal Oncology Service (4640)
  2. Solid Tumor Oncology Division (4640)
  3. Department of Medicine (4638)
  4. Center for Pancreatic Cancer Research (2270)
  5. Surgery (1040)
  6. Survivorship Research (992)

More Groups

People
  1. Leonard Saltz (790)
  2. Eileen O'Reilly (780)
  3. Ghassan Abou-Alfa (568)
  4. Nancy Kemeny (543)
  5. David Kelsen (537)
  6. David Ilson (433)

More People

Years
  1. 2025 (118)
  2. 2024 (307)
  3. 2023 (362)
  4. 2022 (346)
  5. 2021 (345)
  6. 2020 (326)

More Years

Publications
  1. Journal of Clinical Oncology (1276)
  2. Annals of Oncology (320)
  3. Annals of Surgical Oncology (140)
  4. Cancer (127)
  5. Clinical Cancer Research (107)
  6. Cancer Research (94)

More Publications

Publishers
  1. American Society of Clinical Oncology (1355)
  2. Oxford University Press (447)
  3. Elsevier Inc. (404)
  4. Springer (310)
  5. American Association for Cancer Research (279)
  6. Wiley Blackwell (239)

More Publishers

Results (4640)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Treatment response and clinical outcomes of neuroendocrine neoplasms treated with immune checkpoint inhibitors: A single-institution experience
    Meeting Abstract

    Hauser, H.; Le, T.; Chou, J. F.; Heffernan, O.; DeMore, A.; Gonen, S.; Capanu, M.; Reidy, D. L.; Raj, N. P.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Longitudinal trends in health-related quality of life (HRQoL) among patients treated with ivosidenib (IVO) for IDH1-mutated cholangiocarcinoma (CCA) in the ClarIDHy study
    Meeting Abstract

    Chamberlain, C. X.; Hua, Z. W.; Gliser, C.; Pandya, S. S.; Zhu, A. X.; Abou-Alfa, G. K.
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Pivotal phase III COMPOSE trial will compare (177)Lu-edotreotide with best standard of care for well-differentiated aggressive grade 2 and grade 3 gastroenteropancreatic neuroendocrine tumors
    Meeting Abstract

    Halfdanarson, T. R.; Reidy, D. L.; Vijayvergia, N.; Halperin, D. M.; Goldstein, G.; Kong, G.; Michael, M.; Leyden, S.; Grozinsky-Glasberg, S.; Sorbye, H.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015
    Meeting Abstract

    Cohen, D. J.; Tabernero, J.; Van Cutsem, E.; Janjigian, Y. Y.; Bang, Y. J.; Qin, S.; Wainberg, Z. A.; Wang, A.; Hawk, N. N.; Shih, C. S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Pancreatic cancer: Cutaneous metastases, clinical descriptors and outcomes
    Meeting Abstract

    Gu, L.; Paras, M.; Rao, D.; Rotemberg, V.; Capanu, M.; Chou, J. F.; Sigel, C. S.; Busam, K. J.; Boyce, L.; Gordon, A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Nivolumab (NIVO) and drug eluting bead transarterial chemoembolization (deb-TACE): Updated results from an ongoing phase 1 study of patients (pts) with liver limited hepatocellular carcinoma (HCC)
    Meeting Abstract

    Harding, J. J.; Yarmohammadi, H.; Reiss, K. A.; Chou, J. F.; Capanu, M.; Do, R. K. G.; Khalil, D.; El Dika, I. H.; Ferrer, C. S.; Heffernan, O.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A first-in-human phase Ia/b, open-label, multicenter study of the TRAILR2 agonist BI 905711 in patients (pts) with advanced gastrointestinal (GI) cancers
    Meeting Abstract

    Harding, J. J.; Hofheinz, R. D.; Elez, E.; Kuboki, Y.; Rasco, D. W.; Cecchini, M.; Shen, L.; Dowling, E.; Archuadze, S.; de Pereira, B. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA
    Meeting Abstract

    Abou-Alfa, G. K.; Chan, S. L.; Kudo, M.; Lau, G.; Kelley, R. K.; Furuse, J.; Sukeepaisarnjaroen, W.; Kang, Y. K.; Dao, T. V.; De Toni, E. N.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS(G12C) mutation
    Meeting Abstract

    Bekaii-Saab, T. S.; Spira, A. I.; Yaeger, R.; Buchschacher, G. L.; McRee, A. J.; Sabari, J. K.; Johnson, M. L.; Barve, M. A.; Hafez, N.; Velastegui, K.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma—Trial in progress
    Meeting Abstract

    Catenacci, D. V. T.; Strickler, J. H.; Nakamura, Y.; Shitara, K.; Janjigian, Y. Y.; Barzi, A.; Bekaii-Saab, T. S.; Lenz, H. J.; Chung, H. C. C.; Tabernero, J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save